Adaptive Clinical Trial Design ... Clinical Trials Digital Health Technologies eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Neurodegenerative Disease Oncology Trials Opinion Parkinson's Disease Pediatric Oncology Platform Trials PSYCH PULSE Real-World Evidence site activation Site Management Site Operations study startup Treatment-Resistant ... Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Article Cell and Gene Therapy Clinical Decision Support Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trial Quality Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Neurodegenerative Disease Oncology Trials Opinion Parkinson's Disease Pediatric Oncology Platform Trials PSYCH PULSE Real-World Evidence site activation Site Management Site Operations study startup Treatment-Resistant Depression EMA revoked Tavneos (avacopan) in August 2026 over GCP breaches in the pivotal ADVOCATE trial. FDA approved the same data in 2021. Someone should answer for… When a rare-disease approval survives four years of commercial use and then collapses on data integrity rather than new clinical evidence, the monitoring infrastructure that was supposed to catch deviations in real time failed at every level it was designed to operate. Under ICH E6(R2), the sponsor holds primary accountability for trial conduct regardless of how much operational authority has been delegated to a CRO. Rare-disease trials operate under conditions that make GCP compliance harder to enforce and easier to obscure. ADVOCATE enrolled patients with severe ANCA-associated vasculitis, a population that is small, geographically dispersed, and clinically complex.

Privosegtor has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) as well as Orphan Drug designation from both the FDA and the EMA for ON. ZUG, Switzerland and BARCELONA, Spain, August 10, 2026 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, and Accure Therapeutics, S.L. Building on the ACUITY Phase 2 dataset in optic neuritis and constructive FDA pre-IND feedback, Oculis is also planning an IND submission for Privosegtor for the treatment of acute MS relapses. Privosegtor is an investigational drug and has not received regulatory approval for commercial use in any country. ... Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis also recently announced positive FDA pre-IND feedback supporting a regulatory pathway for Privosegtor in acute MS relapses, ahead of a planned IND submission in the fourth quarter of 2026. ... About Privosegtor Privosegtor, a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis (ON) and other neuro-ophthalmic and neuro-axonal diseases. It has a unique portfolio of three first-in-class new chemical entities programs, pursuing innovative targets and potential game changers in the treatment of serious diseases of the central nervous system: ACT-01 (initially sourced from IDIBAPS-Hospital Clinic, Barcelona, Spain, and the Spanish National Council CSIC and then licensed to Oculis – NASDAQ: OCS) at positive phase II clinical trial completed stage in acute optic neuritis, ACT-02 (initially sourced from the Institute for Research in Biomedicine IRB, Barcelona, Spain, and the Universitat de Barcelona UB) at IND-enabling stage in Parkinson’s disease and ACT-03 at CCS-stage in epilepsy. With an experienced business and scientific team, Accure Therapeutics is one of the few companies that operate in an agnostic fashion on initial science to deliver cutting-edge drugs in CNS.

The newly conferred FTD is a further ... XS411's therapeutic potential to resolve unmet medical needs for global Parkinson's patients. Clinical Progress: XS411 Completed Full Enrollment in China Multicenter Phase II Trial · In July 2026, XellSmart announced the full completion of patient enrollment in China's first "National Center for Neurological Disorders"-led multicenter Phase II registrational trial of XS411 for the treatment of Parkinson's disease... The newly conferred FTD is a further vote of confidence to validate XS411's therapeutic potential to resolve unmet medical needs for global Parkinson's patients. Clinical Progress: XS411 Completed Full Enrollment in China Multicenter Phase II Trial · In July 2026, XellSmart announced the full completion of patient enrollment in China's first "National Center for Neurological Disorders"-led multicenter Phase II registrational trial of XS411 for the treatment of Parkinson's disease. 4, 2026 /PRNewswire/ -- On July 28, 2026, XellSmart announced that XS411, the company's independently developed allogeneic, off-the-shelf injectable iPSC-derived cell therapy candidate indicated for Parkinson's disease—the world's second most prevalent neurodegenerative disorder — has been officially awarded Fast Track Designation (FTD) by the US Food and Drug Administration (FDA). This regulatory designation underscores the US health authority's recognition of XS411's clinical value and potential to address the profound unmet clinical needs in Parkinson's disease treatment, representing a pivotal milestone in its worldwide clinical development and future market access. To date, XellSmart has secured nine INDs for registrational clinical trials across China and the United States. The company holds a global leading position in developing iPSC-derived cell therapies for neurological conditions including Parkinson's disease and amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). Spinal Cord Injury: a First-in-Class IND, now in a Phase I registrational clinical trial in China and the US. The China trial is led by the Third Affiliated Hospital of Sun Yat-sen University. Amyotrophic Lateral Sclerosis (ALS / Lou Gehrig's Disease): a First-in-Class IND & the first China-developed iPSC-derived cell therapy granted the US FDA Orphan Drug Designation in 2023, now in combined Phase I/II trial in China + Phase I trial in the US.

preventing parkinson s disease in the context of movement disorders a narrative review of current evidence and future directions